Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Roche reports sales growth as new drugs ease pressure from biosimilar competition
  2. Rival companies to tap $20bn global market with biosimilars for Humira
  3. Deals this week: Amicus Therapeutics, Janssen Pharmaceuticals, Ionis Pharmaceuticals
  4. M&As this week: Ligand Pharmaceuticals, CVS Health, Mundipharma
  5. Deals this week: Janssen Pharmaceutical, Novartis, Novo Nordisk

Latest Content

Europe’s updated guidelines on atopic dermatitis

The latest update to the consensus-based European guidelines for the treatment of atopic dermatitis in adults and children was published in May this year, replacing the previous set of European guidelines published in July 2012.

How will the UK’s relaxed cannabis regulations impact clinical practice?

The UK home secretary announced that as of November 1, specialist doctors will be given the option to legally prescribe patients cannabis-based products if their patients would benefit from the treatment. This will stop regulations from limiting the disease indications that cannabis-based medicines can be prescribed for, and physicians will no longer need to seek approval from an expert panel for patients to access these medicines.

Sepha Multi-Q Leak Testing System

The Sepha Multi-Q is a standalone, multi-functional, non-destructive leak test system that can be used in combination with interchangeable attachments to fit the full range of container types available on the market today.

Trial design should give Dermira’s AD drug a better shot at Phase IIb success

Dermira’s lebrikizumab Phase IIb trial for atopic dermatitis (AD) has a better shot at statistical and clinical significance with the exclusion of corticosteroid, a class of steroid hormone, use. The outcome should be able to beat efficacy results of Roche’s previous proof-of-concept (POC) trial that tested lebrikizumab with corticosteroids and only achieved a 20% difference versus placebo, the inactive drug or treatment used in a clinical trial.

Roche makes a cautious investment in Ionis’ dAMD drug

Following up on Roche’s first partnership with Ionis Pharmaceuticals for an early-stage pipeline asset for Huntington’s disease, the two companies have signed a second deal, this time focusing on IONIS-FB-LRx, an antisense pipeline drug using Ionis’ advanced Ligand Conjugated Antisense (LICA) technology, which reduces the production of Factor B, a key protein in the complement innate immune system in a broad range of diseases.

ESMO 2018: previewing high-impact, late-breaking abstracts

The 2018 European Society for Medical Oncology (ESMO) Annual Congress will begin in Munich on October 19, where combination therapies and immuno-oncology strategies feature heavily in the highest impact clinical research abstracts. The best studies at the congress, those considered cutting-edge or practice-changing, will be presented during the three plenary sessions, called Presidential Symposia at ESMO.

Could Brazilian-style incentives boost the US biosimilar market?

Nearly 10 years after the Biologics Price Competition and Innovation Act of 2009 created an abbreviated pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-approved reference product, 12 biosimilar products have been approved in the US since March 2015.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top